Avicanna | A Leader in Biopharmaceutical Advancement

Driving Biopharmaceutical Advancements of Naturally Derived and Evidence Based Products

Who We Are

Avicanna Is a Commercial-Stage International Biopharmaceutical Company Focused on the Advancement and Commercialization of Evidence-Based Cannabinoid-Based Products for the Global Medical and Pharmaceutical Market Segments

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars

Corporate Overview

An International Biopharmaceutical Strategy

First pharmaceutical marketing authorization (Trunerox)

2023 revenue of $16.8M, representing 314% growth year over year

Active and commercial business pillars including Medical Cannabis Products, Medical Cannabis Care, Pharmaceutical Products, and Active Pharmaceutical Ingredients.

Addressing a global market opportunity – 20+ countries

Leading Scientific Platform and Intellectual Property Portfolio

Established industry leading R&D and scientific infrastructure

JLABS @Johnson and Johnson incubated – at MaRS

30+ commercialized proprietary SKUs – From R&Ds to international commercial channels

Proprietary and indication specific pharmaceutical pipeline

Research and clinical partnerships with leading academic and clinical institutions

Medical affairs and clinical development platform

Intellectual Property and Brands Owned by Avicanna

Medical Cannabis Products and RHO Phyto – Commercial

Medical Cannabis Pharmacy Platform – Launched August

Pharmaceutical Products – In development and registration stages

Active Pharmaceutical Ingredients – Aureus Santa Marta

Four Commercial Stage Business Pillars

Avicanna’s scientific platform has resulted in 30+ proprietary formulations and commercial products

Including medical cannabis, medical cannabis care, Pharmaceutical products and active pharmaceutical ingredients

Medical Cannabis Care Platform

Medical Cannabis Products

Pharmaceutical Products

Active Pharmaceutical Ingredients

Industry Leading Scientific Platform

Setting the Standard in the Cannabinoid Industry with Advanced and Evidence-Based Products

Scientific Platform

R&D Platform Delivering Advanced and Evidence-Based Cannabinoid Products

R&D headquarters in Toronto, Canada with drug development pipeline including sustained release tablets, transdermal patches and nano-particle formulations.

30+

Proprietary Commercial Products

10+

Scientists

Canadian Government Research Grants Awarded Since 2020

Health Canada Cannabis
Research Licenses to Avicanna
or Institutional Collaborators

Several issued and pending patents

World-class Institutional Collaborations

R&D and Clinical Partnerships Over the Past 6 Years

World-Class Institutional Collaborations

20+ R&D, Pre-Clinical Studies and Collaborations with Canada’s Leading Institutions since 2017

Majority of the research has been conducted in Canada through 4 Health Canada cannabis R&D licenses issued to Avicanna and its academic collaborators.